<DOC>
	<DOC>NCT01053858</DOC>
	<brief_summary>To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.</brief_summary>
	<brief_title>Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>central macular thickness of more than 250 Î¼m and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders neovascularization on the disc or elsewhere or rubeosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>bevacizumab,triamcinolone, intravitreal injection</keyword>
</DOC>